Two-Year tracking shows which psoriasis drug keeps skin clear longer
NCT ID NCT04818385
Summary
This study followed 240 adults in Taiwan with moderate-to-severe plaque psoriasis for about 2 years. It compared how well the approved drug risankizumab kept skin clear compared to other similar biologic treatments that patients were already prescribed by their doctors. Researchers tracked skin improvement, quality of life, and side effects during regular clinic visits to see which treatment provided longer-lasting results.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
China Medical University Hospital /ID# 229961
Taichung, 40447, Taiwan
-
Hualien Tzu Chi Hospital /ID# 238431
Hualien City, 97002, Taiwan
-
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 230016
Kaohsiung City, 807, Taiwan
-
Linkou Chang Gung Memorial Hospital /ID# 253775
Taoyuan, 333, Taiwan
-
National Cheng Kung University Hospital /ID# 253776
Tainan, 704, Taiwan
-
National Taiwan University Hospital - Hsinchu branch /ID# 238432
Hsinchu, 30059, Taiwan
-
National Taiwan University Hospital /ID# 230017
Taipei City, Taipei, 100, Taiwan
-
Taipei Medical University Hospital /ID# 230018
Taipei, 11031, Taiwan
Conditions
Explore the condition pages connected to this study.